diversity of molecules and the resulting analytical challenges chaotic 24 april 2013
TRANSCRIPT
Diversity of molecules and the resulting analytical challenges
CHAOTIC 24 April 2013
Overview
Structure of Dose Analysis at GSK
Techniques at our Disposal
Molecule Diversity
Case Studies
Summary
Structure of Dose Analysis at GSK
Multi discipline team within Bioanalytical Science and Toxicokinetics
– Dose concentration analysis
– Bioanalysis
– Toxicokinetics
Purely analytical and interpretation group
Techniques at our Disposal
HPLC- UV
UHPLC-UV
HPLC or UHPLC – CAD (Charged aerosol detector)
A280
LC-MS/MS
Molecular diversity
Traditional Small molecules
Bio-pharm molecules
Peptides
Intermediates in the manufacturing process– Analysis for genetic toxicolgy screens
Natural products
Case Studies - Small Molecules, Compound A
Method Validated with out issue
All samples and standards diluted 1:1 with water prior to injection to improve peak shape
Typical Injection Volume 3 µL
Flow Rate 1 mL/min
Wavelength 311 nm
Analytical Column 50 x 2.1 mm i.d. Waters BEH C18 1.7 µm
Column Temperature 60 ºC
Run Time 1 min
Typical Retention Time 0.8 min
Mobile Phase A 0.05% TFA
Mobile Phase B Acetonitrile
Isocratic Composition A:B 60:40
Diluent Dimethyl Sulphoxide (DMSO)
Case Studies - Small Molecules Compound A
Consistently High results for formulations in 1.14% (w/v) 10M aqueous sodium hydroxide containing 25mM sodium bicarbonate and up to 1M equivalent D-Mannitol.
Why? Was it the formulation or the analysis?
Investigations into the analytical method suggested it was working as it should
On one set of samples for analysis, wrong set of vials injected (undiluted with water)
Standard peak area considerably higher
Samples with in Specification. (although poor peak shape)
Injection of correct samples gave high results
Case Study - Small Molecules, Compound A
Conclusion -– Standards falling out of solution on the addition of
water.– Samples remain in solution due to presence of
solubilising agent in Vehicle– Not picked up on vehicle interference test in validation
due to difference on the way sample prepared
Assay revalidated using a different diluent not requiring the addition of water
Case Study - Bio-Pharm, Compound B
Protein based molecule
Analysis by Absorbance at 280nm on UV-Vis spectrophotometer
Supplied with solution with known concentration and extinction co-efficient
Response from vehicle greater than acceptable, standard approach
All dilutions to be done in vehicle, and response of blank vehicle to be measured at each analysis point and subtracted from sample response
Case Study - Bio-Pharm, Compound B
In general assay of this type give sample results within ±2% of nominal concentration
This compound ≈ 108% of nominal, although within specification this raised questions as to the accuracy of the method
All investigative work under taken indicated this to true result
Subsequent re-analysis of Stock by Bio-pharm group, found concentration to have changed and as such possible cause of high results.
Case Study – Peptides, Compound C
Molecular Weight 2284 amu
Reasonable solubility in organic/aqueous diluent (9mg/mL)
Range of pKa
Low λmax 220nm (relatively insensitive)
Case Study – Peptides Compound C
Uncommonly large variation in retention time across systems
pH requires close attention
Use of Water or 0.9% (w/v) Aqueous Sodium Chloride (vehicle) as diluent not suitable due to reduced UV response
Requires the presence organic in diluent and acidic pH
Assay validated to within usual parameters
Case Study - Intermediates in the Manufacturing Process, Compound D
Compound D has poor UV chromaphore
HPLC-UV analysis unsuitable for levels required
Ionisation not sufficient for CAD detector
LC-MS/MS method validated in vehicle -10% DMSO in 0.9% (w/v) Aqueous Sodium Chloride
– On edge of acceptance criteria for accuracy and precision at LLQ
– 2 initial runs failed to meet acceptance du to variablility attributed to sample preparation
Case Study - Intermediates in the Manufacturing Process, Compound D
Change of vehicle to 1% Aq. Methylcellulose
Validation attempted with the dilution (x10) as initial validation
Validation runs fail on several occasions due to front and back calibration lines have different response and high variation of QCs
Case Study - Intermediates in the Manufacturing Process, Compound D
Logical conclusion, due to change in vehicle therefore diluted further (x1000)
No change in out come
It appeared that the run performance of assay benefitted from allowing the mass spectrometer to settle for an extended period prior to run.
Initially looks promising during tests, however validation runs continue to fail due to increased variability
Chromatography investigated to assess ion suppression
Appearance of second peak on leading edge observed
Case Study - Intermediates in the Manufacturing Process, Compound D
Second Peak
Case Study - Intermediates in the Manufacturing Process, Compound D
Sample sent for NMR analysis
Confirmed the presence of 2 anomeric forms
Confirmation received from chemist that;
– that in solution 2 anomers are formed
– the anomers have differing MS responses due to one anomer being ionised more readily than the other
– The rate of interconversion was specific to media, pH and temperature
Consequently there was no realistic way to resolve the issues
Acceptance criteria widened for accuracy and precision to 20%
Case Study - Intermediates in the Manufacturing Process, Compound D
TertiaryButylamine
No UV chromaphore
MW 73 amu
Simple structure, volatile
Classic method of analysis GC-MS, not available to us.
CH3
CH3
CH3
NH2
Intermediates in the Manufacturing Process Compound E
Attempted derivitisastion to allow LC-MS/MS analysis failed
Analysis not possible without derivitisation due to;– no retention on reverse phase chromatography– poor ionisation in MS source– no fragmentation (although possible to use SIM)
No way of telling if the all the all the TBA had been derivitised
Possibility of using accurate mass instrument (Waters Synapt G2-S, quantitative ToF) but not GLP validated
Contracted out for analysis by GC-MS
Case Study - Natural products, Compound F
Mono/Oligosaccharides
UV not suitable CAD Detection required
What peaks to monitor?
Soluble Insoluble
Case Study - Natural products, Compound F
Validated HPLC ConditionsHPLC System Agilent 1100Typical Injection Volume 5 L
Flow Rate 1 mL/minAnalytical Column
Waters XBridge Amide, 3.5 m, 150 x 4.6 mm
Column Temperature 45C
Run Time 50 minutesTypical Retention Time
Approximately 24.5 minutes (Peak 1) Approximately 29.2 minutes (Peak 2)
Mobile Phase A (90:10) Acetonitrile:Water containing 0.02% (v/v) NH4OH
Mobile Phase B (50:50) Acetonitrile:Water containing 0.02% (v/v) NH4OH
Time (mins) %A %B
0.0 95 5
2 95 5
42 25 75
42.1 95 5
Gradient profile
Case Study - Natural products, Compound F
HPLC-CAD Chromatogram
Case Study - Natural products, Compound F
For quantification, sum of 2, 3-chain sugars
Sum of areas means transfer to excel and 100% check of data
Poor sensitivity reference standard at 15mg/mL
23 days stability generated @ room teperature
Case Study - Natural products, Compound F
Anthocyanin analysis
Warned about lack of stability
Diluted in 10% phosphoric acid to increase stability
Unstable in light (>40% loss in 12 hours on the bench) confirmed even with acid
All work done in amber glassware
Case Study - Natural products, Compound F
Validated HPLC ConditionsHPLC System Agilent 1100Typical Injection Volume 10 L
Flow Rate 0.8 mL/minAnalytical Column
250 x 4.6 mm i.d. LiChrosorb RP 18.5 µm
Column Temperature 35C
Run Time 25 minutes
Typical Retention Time
Peak 1: ~10.79 minPeak 2: ~11.17 minPeak 3: ~13.24 minPeak 4: ~14.39 min
Mobile Phase A 10% Formic Acid (FA)
Mobile Phase B (75:15:10) Water:Acetonitrile:Formic Acid
Time (mins) %A %B
0.0 70 30
20 70 30
20.1 0 100
25 70 30
Gradientt profile
Case Study - Natural products, Compound F
HPLC-UC Chromatogram of Anthocyanins
Case Study - Natural products, Compound F
For quantification, sum 4 separate anthocyanins
Sum of areas means transfer to excel and 100% check of data
6 Days stability generated in acidic conditions, protected from light
Summary
Dose analysis set up slightly different at GSK with a pure analytical that also performs other analytical tasks
Dose analysis has to develop and validate method suitable for quantification of highly varied compounds
Ready access to a variety techniques
Still some things are beyond our capability
This set up allows the dose analysis group to be true analytical experts and better placed to deal with diversity
Acknowledgements
Amanda Foster
Tammy Clegg
Aida Merchan
Connie Parker
Mark Mullin (RTP)
Back Up
CAD